Pfizer and Soth Korea’s Samsung Biologics Ink $900M Partnership for Biosimilar Production: Details
South Korean contract development and manufacturing organization Samsung Biologics and Pfizer Inc (NYSE: PFE) have signed two agreements for the long-term manufacturing of Pfizer's multiproduct biosimilar portfolio, worth $897 million.